Delisting riskPopularity #4,178
aTyr Pharma (ATYR)
Develops efzofitimod and tRNA-synthetase-derived therapies for fibrosis and inflammation.
$0.3664
vs last close+0.01 (+2.81%)
Something off on this page? Send us feedback.
Next report
Nov 5, 26
in 43 days
EPS estimate
−$0.11
Revenue estimate
$2.5M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.18−$0.17−$0.22−$0.26−$0.14−$0.11−$0.11Pending
Estimate−$0.23−$0.19−$0.18−$0.20−$0.18−$0.16−$0.12−$0.11
Surprise+21.7%+10.5%−22.2%−30.0%+22.2%+31.3%+9.4%—
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported———$190.0K——$189.6MPending
Estimate$15.6K——$20.0K$40.0K——$2.5M
Surprise———+850.0%————
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2027 | −$0.09 | — | — |
| Sep 2027 | −$0.10 | — | — |
| Jun 2027 | −$0.09 | — | — |
| Mar 2027 | −$0.10 | — | — |
| Dec 2026 | −$0.09 | — | — |
| Nov 2026 | −$0.11 | — | — |
| Aug 2026 | −$0.12 | −$0.11 | +9.4% |
| May 2026 | −$0.16 | −$0.11 | +31.3% |
| Mar 2026 | −$0.18 | −$0.14 | +22.2% |
| Nov 2025 | −$0.20 | −$0.26 | −30.0% |
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Sep 2023 | |||
| Jun 2023 | |||
| Mar 2023 | |||
| Mar 2023 | |||
| Dec 2022 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| Jun 2022 | |||
| Mar 2022 | |||
| Dec 2021 | |||
| Sep 2021 | |||
| Jun 2021 | |||
| Mar 2021 | |||
| Dec 2020 | |||
| Sep 2020 | |||
| Jun 2020 | |||
| Mar 2020 | |||
| Dec 2019 | |||
| Sep 2019 | |||
| Jun 2019 | |||
| Mar 2019 | |||
| Dec 2018 | |||
| Sep 2018 | |||
| Jun 2018 | |||
| Mar 2018 | |||
| Dec 2017 | |||
| Sep 2017 | |||
| Jun 2017 | |||
| Mar 2017 | |||
| Dec 2016 | |||
| Sep 2016 | |||
| Jun 2016 | |||
| Mar 2016 | |||
| Dec 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2027 | −$0.09 | — | — | $44.0M | — | — | — |
| Sep 2027 | −$0.10 | — | — | $18.8M | — | — | — |
| Jun 2027 | −$0.09 | — | — | $7.5M | — | — | — |
| Mar 2027 | −$0.10 | — | — | $0 | — | — | — |
| Dec 2026 | −$0.09 | — | — | $9.7M | — | — | — |
| Nov 5, 2026 | −$0.11 | — | — | $2.5M | — | — | — |
| Aug 7, 2026 | −$0.12 | −$0.11 | +9.4% | — | $189.6M | — | +3.4% |
| May 15, 2026 | −$0.16 | −$0.11 | +31.3% | — | — | — | −10.0% |
| Mar 5, 2026 | −$0.18 | −$0.14 | +22.2% | $40.0K | — | — | −6.5% |
| Nov 6, 2025 | −$0.20 | −$0.26 | −30.0% | $20.0K | $190.0K | +850.0% | −5.4% |
| Aug 7, 2025 | |||||||
| May 7, 2025 | |||||||
| Mar 13, 2025 | |||||||
| Nov 7, 2024 | |||||||
| Aug 13, 2024 | |||||||
| May 2, 2024 | |||||||
| Mar 14, 2024 | |||||||
| Sep 30, 2023 | |||||||
| Jun 30, 2023 | |||||||
| Mar 31, 2023 | |||||||
| Mar 9, 2023 | |||||||
| Dec 31, 2022 | |||||||
| Nov 10, 2022 | |||||||
| Aug 15, 2022 | |||||||
| Jun 29, 2022 | |||||||
| Mar 30, 2022 | |||||||
| Dec 30, 2021 | |||||||
| Sep 29, 2021 | |||||||
| Jun 30, 2021 | |||||||
| Mar 31, 2021 | |||||||
| Dec 31, 2020 | |||||||
| Sep 30, 2020 | |||||||
| Jun 30, 2020 | |||||||
| Mar 31, 2020 | |||||||
| Dec 31, 2019 | |||||||
| Sep 30, 2019 | |||||||
| Jun 30, 2019 | |||||||
| Mar 31, 2019 | |||||||
| Dec 31, 2018 | |||||||
| Sep 30, 2018 | |||||||
| Jun 30, 2018 | |||||||
| Mar 31, 2018 | |||||||
| Dec 31, 2017 | |||||||
| Sep 30, 2017 | |||||||
| Jun 30, 2017 | |||||||
| Mar 31, 2017 | |||||||
| Dec 31, 2016 | |||||||
| Sep 30, 2016 | |||||||
| Jun 30, 2016 | |||||||
| Mar 31, 2016 | |||||||
| Dec 31, 2015 |